Repligen (NASDAQ:RGEN) Given New $170.00 Price Target at Canaccord Genuity Group

Repligen (NASDAQ:RGEN) had its price target upped by Canaccord Genuity Group from $165.00 to $170.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price target would indicate a potential upside of 4.51% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $180.00 target price on shares of Repligen in a research report on Friday. Finally, TD Cowen initiated coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $183.36.

Repligen Trading Up 7.9 %

Repligen stock opened at $162.67 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen has a 1 year low of $113.50 and a 1 year high of $203.13. The firm’s 50-day moving average is $155.17 and its 200-day moving average is $148.81. The company has a market cap of $9.11 billion, a P/E ratio of -439.64, a PEG ratio of 4.23 and a beta of 0.99.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. On average, equities analysts expect that Repligen will post 1.54 earnings per share for the current year.

Institutional Trading of Repligen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RGEN. UMB Bank n.a. raised its position in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares during the last quarter. First Turn Management LLC acquired a new stake in Repligen during the third quarter valued at approximately $13,202,000. Thrivent Financial for Lutherans grew its position in Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after acquiring an additional 36,773 shares during the period. Geneva Capital Management LLC grew its holdings in shares of Repligen by 8.5% in the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock worth $20,638,000 after purchasing an additional 10,908 shares during the last quarter. Finally, TimesSquare Capital Management LLC increased its holdings in shares of Repligen by 14.6% during the third quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company’s stock worth $41,019,000 after buying an additional 35,115 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.